Abstract
Background: COVID-19, a disease caused by SARS-CoV-2, manifests with headache, both in the acute phase and as a post-infection symptom, which may be refractory to usual analgesics.
Objectives: Investigate the therapeutic response of refractory COVID or post-COVID headache to indomethacin.
Methods: This was an observational, retrospective, open and uncontrolled. A sample of 37 patients diagnosed with COVID-19 presenting headache during the acute phase or after the resolution of the disease, with refractoriness to the usual symptomatic medication was treated with indomethacin.
Results: Of the 37 patients (24 women and 13 men), 29 were migraineurs and 8 had no previous history of headache. The average age was 40.4 ± 9.4 years, ranging from 19 to 65 years. In 26 (70.3%) patients, the onset of headache occurred within 72 h, and in 11 (29.7%), after 10 days of positivity for Sars-CoV-2. After treatment with indomethacin, 36 patients reported greater than 50% headache relief from the third day and 5 became asymptomatic on the fifth day.
Conclusions: In patients with migraine or no prior history of headache who present with refractory COVID or post-COVID headache to common analgesics, anti-inflammatory drugs, and/or triptans, indomethacin should be considered a therapeutic option.
Keywords: Abortive treatment; Indomethacin; Post-COVID headache; Refractory headache.
【저자키워드】 indomethacin, Abortive treatment, Post-COVID headache, Refractory headache., 【초록키워드】 COVID-19, Treatment, SARS-CoV-2, Anti-inflammatory drugs, Symptom, headache, COVID, Asymptomatic, symptomatic, Patient, age, women, medication, disease, patients, retrospective, therapeutic option, Post-infection, acute phase, average, refractory, men, therapeutic response, greater, occurred, caused, reported, the disease, treated, had no, presenting, diagnosed with COVID-19, 【제목키워드】 COVID, Retrospective study,